DocGo Inc. (DCGO) Earnings Call Transcript & Summary

August 9, 2022

NASDAQ US Health Care Health Care Providers and Services earnings 54 min

Earnings Call Speaker Segments

Steve Halper

executive
#1

I appreciate that, Irene. Ahead of handing things to the management team, I'd like to offer a few comments about forward-looking statements. Everything said on this conference call that isn't a historical fact qualifies as a forward-looking statement. Terms such as anticipate, believe, estimate, expect, intend, guidance, confidence, target, project, along with comparable expressions, are typically how we flag those forward-looking statements; such statements don't promise future performance and could involve and are subject to certain risks, uncertainties and other factors that might impact DocGo's business, financial condition and other operating results. Among these are, without limitation, the risk factors and other qualifications found in DocGo's Form 10-K annual report, its Form 10-Q quarterly reports, and other reports and statements DocGo has filed with the SEC, to which we direct your attention. What actually happens and the results we achieve could differ materially from what these forward-looking statements express or imply. Also, references to non-GAAP financial measures appear in today's presentation, and reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in our earnings release and in our filings with the securities and exchange commission. What's shared on this call is accurate only as of the date discussed. Investors shouldn't assume such statements stay relevant and operative later on. We assume no obligation to update any information discussed on this call in the future. With that, I'm pleased now to hand the call to Mr. Stan Vashovsky, CEO and Co-Founder of DocGo. Stan?

Stan Vashovsky

executive
#2

Thanks, Steve. I also want to thank everyone for being with us today. Q2 was yet another stretch of solid operational performance. Our top line climbed 76% compared with the same quarter last year, reaching $109.5 million. With sales continuing to gain traction and contributions from acquisitions, we have lifted our 2022 revenue outlook to a range of 425 million to 435 million, up from the earlier range of 400 million to 420 million. We are likewise increasing our adjusted EBITDA guidance to a range of 40 million to 45 million, versus the original guidance of 35 million to 41 million. A number of key drivers are behind our ongoing organic growth, among them the broadening of our agreements with Carnival Cruise Lines, new municipal programs in New York, new mobile health programs in Los Angeles, and an expanded medical transportation business with Northwell. Revenue from mass COVID testing during the quarter came to roughly 28 million, and we expect that figure to fall substantially in the third quarter. We have already started replacing it with non-COVID related business that is in place, and in many instances the customers stay the same. One illustration of this in New York is our shift from mass COVID testing with a municipal client straight into delivering primary care at homeless shelters or medical imaging services for that same client; in certain cases, we anticipate the move to these new non-COVID projects will be fairly seamless, with only a minimal effect on generating revenue. When it comes to M&A, we expect our activity to pick up, with several prospective transactions in the pipeline that have us very excited; we keep chasing synergistic opportunities where prospective targets might currently be outsourcing services that DocGo could deliver directly. That comes on top of those opportunities that unlock new markets and drive improved profitability. Our aim is to keep leveraging a strong balance sheet and cash flow from operations to broaden the breadth, depth and profitability of the company's portfolio of services. We keep doing a great job, both winning your customers and deepening those relationships substantially over time. Last quarter, we shared the statistic that roughly 90% of DocGo's revenues come from customers in the third, fourth or fifth generation contract, and that trend holds true today; this success has played out across every variety of customer, from corporations to healthcare systems and municipal accounts. This achievement says a great deal about our capacity to get our foot in the door, deliver exceptional value to the customer and grow that business considerably. We have also markedly strengthened our RFP capabilities in recent months, which lets us actively bid on larger contracts across the country; while it is too early to quantify expectations, the pace of activity in this channel has more than tripled lately, and we anticipate a meaningful contribution from these efforts as we enter 2023. It is clear that the municipal customer segment will stay a cornerstone of our business for the foreseeable future, giving us a stable base of revenue on which we can build. The results we're seeing from our direct-to-consumer and corporate health data tests keep being really encouraging. There's a huge opportunity in that direct-to-consumer market, and we've teamed up with several of the biggest payers in the industry, among them Aetna, BlueCross, and LA Care; with these partners, we anticipate coordinated marketing efforts kicking off in late 2022 and early 2023. There's one market I'd like to spend a moment on and go through in more depth, and that's the cruise line business, since it serves as a great case study on what DocGo's services are worth to the customer. At the start, we came into this market with a fairly small contract, delivering COVID related testing services to Carnival staff in early 2021. By the end of 2022, we expect to be facilitating full spectrum of standard healthcare services, doctors down to lower-level clinicians, a majority of Carnival's fleet. During 2022, we started serving two additional major cruise lines that we expect to follow a similar growth trajectory. How quickly those first contracts scaled up underscores how appealing DocGo's unique model is, along with our dedication to customer service. That success also shows up in our NPS, or net promoter score, which is the gold standard of customer experience metrics. Scores are measured from a range of negative 100 to positive 100 with scores over 30 commonly viewed as good with over 50 being considered excellent. Our Q2 mobile health NPS score came in at an impressive 77, which speaks to how strongly our customers perceive the value of DocGo's service. Another illustration of ongoing business execution comes from a major hospital system in Southern California; this customer utilizes DocGo's emergency room avoidance program, which attempts to mitigate unnecessary emergency room visits. Through our program, we delivered a 35% reduction in ER visits, which generated meaningful financial savings for that institution and earned bonus payments to DocGo for hitting that goal. Ultimately, our proprietary technology is the lifeblood that lets us provide efficient, cost-effective healthcare in a mobile setting; and we're putting further substantial investments behind the next-generation of functionality. Right now, I'll pass things to Anthony Capone, our President, so he can give us some details on that front. Anthony?

Anthony Capone

executive
#3

Thank you, Stan. DocGo is fundamentally a technology business, and having served as its previous Chief Technology Officer, I've watched our software grow into an extremely advanced platform. During Q2, we significantly upgraded our dispatching application, adding the capability to allocate mobile health and ambulance resources according to predictive demand analysis; this advanced model drives higher utilization, which cuts down idle time for our mobile units and strengthens our capacity to provide our affordable healthcare. Our team additionally created a very smart machine learning system that aids in forecasting reimbursement and helps secure collectability. Here at DocGo, we've developed software that sits at the center of our business model and connects with systems that underpin our operations. In Q2, we finished integrating with Athenahealth, one of the country's biggest EHRs. On top of that, DocGo has been welcomed into the Epic app portrait as its first and, at present, sole fully embedded mobile health ordering application. Membership in the Epic app portrait gives the thousands of hospitals that use Epic the chance to order DocGo services straight from inside their native EHR. DocGo stands behind virtual and mobile first medicine, and to advance that vision we've upgraded health point, our patient EHR system, by incorporating telehealth support, which guarantees a smooth in-app patient experience. Software and automation sit at the center of our company. And across the years ahead, DocGo will keep putting tens of millions of dollars into our engineering team. Stan, I'll turn it back over to you.

Stan Vashovsky

executive
#4

Appreciate that, Anthony. Following a really strong quarter, we still see enormous room to grow, and that opportunity will come through a number of distinct paths over the coming years. Right now, I'll pass things along to Andre Oberholzer so he can walk through the financial specifics.

Andre Oberholzer

executive
#5

Thanks, Stan, and good morning everyone. Looking at the second quarter of 2022, our total revenue was 209.5 million. Compared with the 62.2 million we reported in Q2 of '21, that represents 76% growth. What drove that increase year over year? Mainly revenue from the continued expansion of major corporate accounts due, along with growing municipal mobile health contracts, and also gains in important medical transportation customer relationships, such as Northwell. Turning to mobile health, revenue for Q2 of 2022 came to 87.3 million. In Q2 of '21, that figure was 33.2 million, so we're looking at an increase of roughly 163%. Excluding all revenue from mass COVID testing in each quarter, mobile health brought in $59.3 million, up from $23.2 million in the prior year — a 156% improvement. Medical transportation overall totaled $22.2 million, compared with $28.9 million during the second quarter of 2021. Transportation that recurs rose to $20.2 million from $18.7 million a year earlier, marking an 8% gain. One thing to keep in mind: roughly $10.2 million of project-based standby transportation revenue sat in last year's Q2, which funded emergency deployments for a range of municipal agencies providing standby coverage at testing and vaccination locations. By the end of 2021's second quarter, those emergency deployments had gradually tapered off. Project-based emergency deployment revenue in Q2 2022 was approximately $2 million. During this year's second quarter, mobile health brought in 80% of all revenue. That compares to 53% during the same period last year, while transportation made up the remainder. The UK market generated 45% more revenue, reaching 3.2 million in this year's Q2, which works out to roughly 3% of overall revenue. Net income for the second quarter of 2022 came to 11.8 million — a huge jump from the $100,000 in net income per quarter recorded a year before. It's worth noting that net income figures include a gain of roughly 3 million tied to remeasuring warrant liabilities, plus 1.4 million from remeasuring finance leases. After removing those particular items, our net income for Q2 exceeded $7 million. The quarter's revenue growth was strong, and that, along with improved overall gross margin, drove the net income gain, while some infrastructure-related overhead expenses provided leverage because they increased at a slower rate than revenues did. Adjusted EBITDA for the second quarter of '22 climbed to 12.3 million, compared with 3.4 million a year earlier, despite the extra investments we put into regional expansion, product offerings, and infrastructure. Keep in mind that adjusted EBITDA is a non-GAAP metric that stands for earnings before interest, tax, depreciation, amortization, stock-based compensation, warrant and finance lease liability revaluation, and other non-recurring expenses. Regarding the reconciliation between adjusted EBITDA and net income, please see our earnings release, as Lease mentioned. During 2022's second quarter, total gross margin reached 35.9%. In the comparable period of 2021, that figure stood at 34%. One thing worth noting: despite inflationary pressure driving up expenses tied to labor and other items within cost of sales, DocGo still pulled off year-over-year improvement in gross margin on a consolidated basis. The mobile health segment generated that 1.9% increase in total gross margin percentage, with gross margins climbing from 28% during last year's Q2 to 39.9% in this year's second quarter. A number of factors came together to drive the gross margin improvement in mobile health. Lower laboratory fees played a part, as did our ongoing shift away from costlier subcontracted labor, which accounted for a much smaller portion of mobile health revenue in the quarter just ended than it did in the same period a year ago. Partly working against those positive trends were increased expenses for some labor-related supplies. In transportation, gross margin came in at 20% during this year's second quarter, compared with 22.7% in the first quarter. Rising hourly pay over time, along with a significant increase in fuel costs, continue to weigh on our transportation gross margin in the current year. During last year's transportation results, we benefited from having included over 10 million in emergency deployment standby revenues, which carried high margins. At the end of the second quarter, which closed on June 30, 2022, we held 208 million in total cash and cash equivalents. That compares with 199 million when Q1 wrapped up earlier in the year, and 179 million at the conclusion of fiscal 2021. Operations generated 30 million in positive net cash during the first six months of 2022, while the same stretch a year earlier saw 1.1 million used in operations. Excluding vehicle leases, our outstanding debt stood at 2.6 million when Q2 ended, up from 1.9 million at the close of last year. DocGo rolled out a buyback plan in May of this year allowing for as much as 40 million in common stock repurchases. Through that initiative, during the quarter we repurchased 70,000 shares, paying an average of $7.10 apiece. On the topic of inflation's effect on us, as we've noted previously, two primary cost areas exist where rising prices could have a significant bearing on our performance. When we issued our 2022 guidance at the beginning of this year, we built in an assumption that labor's average hourly expense would climb roughly 7% compared with 2021's already elevated wage rates, along with an average goods cost of $4.30 per gallon. Looking at Q2 2022, the average hourly labor rate came in above what we actually saw a year ago, yet it landed below the figures we had assumed. Meanwhile, the cost per gallon of fuel climbed sharply, exceeding both last year's level and the rates we had forecast. In this year's second quarter, higher gas expenses dragged gross margin down by roughly 73 basis points relative to Q2 2021, and by 55 basis points when measured against our 2022 assumptions. On the labor side, the bump in the average hourly rate versus the prior year hurt margins by 129 basis points during this year's Q2. However, actual average hourly pay rose less quickly than our 2022 projection, which benefited gross margins by about 94 basis points relative to what we had forecast. Revenue from COVID testing dropped to 28 million during ’22’s second quarter, compared with 38 million in the first quarter. Remove COVID testing revenue from both quarters of this year, and mobile health revenue increased 13%, reaching 59.3 million in ’22’s second quarter versus roughly 52 million in the first. Going forward, as we previously stated, COVID-related testing revenue will no longer be broken out from total revenue. During Q2 of 2022, adjusted EBITDA reached 12.3 million, representing about 11.2% of revenue — a figure that was nearly identical to the 11.5% EBITDA margin posted in Q1 and above the 9.3% annual guidance we had provided at the beginning of the year. Revenue for the six months that ended June 30, ‘22 totaled 227 million, reflecting 104% growth compared with last year’s total revenue of 112 million. For that same six-month period ending June 30, ’22, adjusted IBITDA was 25.9 million, a significant gain versus last year’s adjusted EBITDA of 3.8 million; moving now to our ‘22 outlook, we anticipate robust customer demand across both mobile health and transportation services. Stan already touched on this, but because our results so far this year have been strong, we're lifting the revenue outlook from 400 million to 420 million up to 425 million to 435 million. Our adjusted EBITDA outlook is also going up, from 35 million to 41 million to 40 million to 45 million. That works out to year-over-year revenue growth of 33% to 36%, and adjusted EBITDA as a percentage of revenue should rise to roughly 10% this year, compared with 7.9% in fiscal '21. Turning to segment revenues, we anticipate mobile health will continue to account for about 74% to 76% of revenues, with medical transportation providing the remainder. That concludes our prepared remarks. Right now, we're going to have the operator start taking questions from callers. Thanks.

Richard Close

analyst
#6

Andre, maybe this is just administrative detail, but could you possibly give us the transportation volumes along with pricing for the quarter? Then, when we consider how fast transportation is growing on the recurring revenue side, I'm curious what you think about that 8% growth. Going forward, ought we to expect a figure higher than that? Or what's the right way to think about recurring revenue growth in transportation?

Andre Oberholzer

executive
#7

Regarding actual volume and price per trip, we haven't disclosed those figures at this moment; it will appear in <<inaudible>>, perhaps filed with the SEC. Once the results are out, you'll observe a rise in trip volume and also a rise in price per call, and together those produced the 8% year-over-year increase. Project-based labor is not included there, so it's recurring only. As has been true previously, you should still expect transportation to expand roughly 30% year-over-year. At this moment, we don't anticipate that pattern shifting.

Stan Vashovsky

executive
#8

Richard, this is Stan — great to speak with you once more. And, as we went over previously, the way our company makes money has changed across the past several years, to the point where counting how many trips happen in a day simply doesn't matter anymore, given how we bill our clients through what we call our least hour program. The result is that the customer pays us an identical dollar figure; they're charged at — let's say a minimum rate per day, and that covers the vehicle, cruise supplies, all of it. That means whether that one vehicle handles one transport for that one customer or handles seven transports, what we're paid for that day doesn't change. This serves to smooth out the slower days against the busier ones, adding a bit of consistency and letting us plan our business with greater confidence; it also gives the customer peace of mind that their resources are dedicated rather than on demand, which in the past has shown itself to be somewhat non-reliable.

Richard Close

analyst
#9

All right. That said, a 30% growth rate is a solid one in transportation. I just want to —

Andre Oberholzer

executive
#10

Yes, for the year, we're still going to hold to 30% growth, within that range.

Richard Close

analyst
#11

All right. Also, is there any revenue in 2021's third quarter that isn't recurring that we ought to know about?

Stan Vashovsky

executive
#12

Richard, projecting that is somewhat difficult. At this point, we aren't projecting a great deal, yet the truth is a hurricane could arrive tomorrow. There could be a forest fire in California, where FEMA notifies us. State agencies notify us to come in and help. Those are one-time services based on projects. They occur multiple times over the year, yet projecting them is really tough; however, we will always be extremely conservative and say we can hit our growth target using what we can count on, which is our contracted business. We don't know whether Q3 will include that one-time, call it project based emergency response that we've had before <<inaudible>> will likely have a small amount of it there, but there's no way to measure how much of it will land in Q3.

Andre Oberholzer

executive
#13

When we look at how things went a year ago, though, there wasn't much revenue tied to specific projects during Q3. The bulk of that activity had already wrapped up by the time Q2 of last year came to a close.

Richard Close

analyst
#14

Then, Stan, regarding the M&A opportunity — could you perhaps elaborate a bit more on that? From what you said, it sort of seemed like you're spotting chances in mobile health, possibly involving extra services. Did I get that right? Or do you have any other views on M&A?

Stan Vashovsky

executive
#15

Yes, that's exactly right, Richard. When it comes to M&A, mobile health services are where we're focused; we believe opportunities will arise. More and more of them are beginning to come our way. Hopefully, before long, we'll close on a few of them. On the transportation side, we will always buy licenses and tiny companies, since that's simply the best route to obtain a license and enter a market. You could apply for one, yet you might end up waiting 6, 12, 24 months while dealing with the municipality for a license, whereas you can shell out a few hundred dollars to buy a small company and then treat that license as your entry point. So there will always be what you might call license purchases on the transportation side, but the bulk of what you could call our capital is being held back for a sizable amount of M&A activity down the road centered on mobile health. That's the area we're most thrilled about. It's growing very quickly, and we see boundless possibilities. We see plenty of areas that interest us greatly, where we've demonstrated we can be highly effective. And that's how we intend to deploy our capital.

Michael Latimore

analyst
#16

So I suppose regarding the guidance, the press release mentions that the outlook was raised because of organic growth plus M&A activity that took place after the quarter ended. That sort of makes it sound like an acquisition has already happened, or am I reading that wrong?

Stan Vashovsky

executive
#17

No, your interpretation is right. We completed a recall — the term we use is tuck-in acquisitions, meaning small deals that provide licensing capabilities. So no material sum of money has been spent by us. We haven't brought in any material revenue, but we always, I mean, historically 5, 6, 7 small companies, we treat our licenses as launching points; and nothing we've done would be called material, Richard — I mean, Mike; but historically, if you examine our patterns, each quarter we invariably purchase some tiny mom-and-pop shop somewhere for its license.

Michael Latimore

analyst
#18

So would you say organic efforts account for the bulk of that gain?

Stan Vashovsky

executive
#19

Almost the entire amount. What I'd add is that frequently we'll bring in a business whose sales might only total a few million dollars, yet that isn't the sort of operation we'd choose to retain regardless; as a result we'll let those sales go and put our attention instead on how we prefer to run things.

Michael Latimore

analyst
#20

The gross margins were clearly strong. Should we think of them as fairly sustainable around this level, or could there be opportunity for them to grow in the back half of the year?

Stan Vashovsky

executive
#21

Mike, the truth is, we will keep improving them no matter what. We continue to pay a premium for staffing, while the market keeps talking about cutting back on staffing — our approach is the reverse: we're bringing people on at full speed; we're covering recruiter costs, we're covering staffing agency costs, and we're still surrendering quite a bit of margin that I believe will level out over time, which will help push and keep validating our gross margin; we've consistently stated that mobile health should ideally sit at roughly 42%, 43% gross margin, with transportation a bit under that. So room remains for growth and improvement.

Michael Latimore

analyst
#22

Then, finally, on what you mentioned about hiring — your goal of bringing on 600 people before the year is out. Of that group, how many represent genuinely net new roles as opposed to backfilling someone supplied by a staffing agency?

Stan Vashovsky

executive
#23

Every bit of that 100% adds to the headcount we have today. So with what we currently have, that figure of 600 excludes anyone brought in to cover attrition. It rests purely on the workload contracts already signed, with start dates and agreed work we expect in Q2 of this year. Our demand for clinicians and operational staff remains very strong. We have a recruiting team numbering more than 20 individuals. We also work with a large number of agencies that assist in sourcing candidates. So we keep hiring as aggressively as — nearly as aggressively as we did last year.

Andre Oberholzer

executive
#24

Andre here, Mike — I’d like to make one point clear when it comes to Safe for Mobile Health. Our contracts continue to be priced with a target margin of roughly 50% to 53%. Given the gain you observed in Q2 from using subcontract labor, we’re moving along that route toward those intended margins.

Sarah James

analyst
#25

You folks just posted a very impressive quarter when it comes to getting contracts inked. In the release, I believe you inked Carnival LA Care along with Empire Blue Cross. Could you provide any sense of how large those are, or how we ought to approach modeling new contract additions where transportation revenue is concerned?

Stan Vashovsky

executive
#26

Well — that's an excellent question, Sarah; we generally don't give specifics at the individual customer level. Sharing that sort of data is something our customer agreements forbid us from doing. As for modeling, the only thing I can tell you is that our history of hitting and exceeding guidance is quite solid. We're quite confident about the municipal contracts, the hospital contracts that we signed, the share of customers making the shift from work tied to COVID to work not tied to COVID is very high, well above 80%. And I'd simply say that throughout the country, municipal work is going to remain our largest contributor. We have a few quite distinctive programs that, in my view, set DocGo apart from other medical providers, and after that come hospitals and insurance companies. Andre, is there anything more you'd like to add? Or what's your take, Andre?

Andre Oberholzer

executive
#27

Nope, that's fine. I mean, when you compare it with the prior year, we're looking at roughly 30% to 36% growth this year in those sorts of contract systems, as things progress.

Stan Vashovsky

executive
#28

Allow me to tack on a single additional point. We reference expansion of 30% to 36%, yet should you compare last year's figure of 319 against the outlook we've given for this year, the truth is that the 319 from the prior year includes roughly 40 million, 50 million tied to COVID testing. That won't carry over into the current year. So should you lower that 319 down to, say, 250, that represents the genuine additional business we are out there winning. Thus it has been a fantastic year. We are quite enthusiastic about the year, demand for what we offer keeps being incredibly robust. We deliver clinical services in a manner our rivals do not, highly inventive and heavily tech-driven. So it's 30%, 35% when viewed from the close of last year, yet in truth that figure sits nearer to 50%, 60% once you strip out the second half portion of COVID testing from last year, which we don't expect to be a significant contributor this year.

Sarah James

analyst
#29

Could we get a bit more detail on your pipeline for new clients — whether that's municipal RFPs or talks with providers — and how it stacks up against last year?

Stan Vashovsky

executive
#30

It's strong, very strong. As we've mentioned previously, and this is something we feel great about, what's left of the COVID business amounts to just two, let's say, significant customers that we still perform mass COVID testing for. One of those contracts ends in early September, while the second is very, very small. Here's what makes us especially proud, and I believe it says a great deal about what our company has accomplished: that very same customer is transitioning away from a COVID program toward a purely mobile health, traditional-style program. In that same arrangement, both the staff and the revenue they brought in will keep on working — nobody gets laid off. They'll simply arrive, receive a bit of extra training internally, and then be reassigned, often serving that very same customer. We've already factored in every dollar of revenue we anticipate losing from the mass COVID testing locations during the back half of the year. That entire amount will come from traditional mobile health — completely unrelated to COVID testing, COVID vaccinations, or anything tied to COVID.

Analyst

analyst
#31

Hello, Ryan here, filling in for Pito. I appreciate you taking my question. I just wanted to revisit the topic of margins. I heard what you said about the strong 2Q gross margin, and you believe that level can be sustained moving forward, but the guidance seems to imply at least some decline in 2H. So I just wanted to understand, is that simply the winding down of the COVID testing revenue, or is it some caution regarding labor and fuel costs? Or could you elaborate a bit further on that shift in margins going into 2H?

Stan Vashovsky

executive
#32

Andre, would you like to handle that?

Andre Oberholzer

executive
#33

Okay, let me try this. When it comes to the drop in COVID testing, gross margin really isn't affected, since all our mobile health pricing—COVID testing included, and that's mass testing rather than consumer—gets priced at roughly the same margin, somewhere from 50% to 53%. So when the COVID program winds down and we shift over to your mobile health replacement program, the margin stays basically the same. Looking at the second half, we keep monitoring inflation and gas prices, which came in higher than we'd anticipated during Q2. That accounts for a few basis points. Labor is too holy, but we always prefer guidance that carries some conservatism—no actual margin decrease is planned on our side, apart from you examining inflation and considering how it hits the second half.

Stan Vashovsky

executive
#34

Let me just say as well that when it comes to the guidance we give on revenue and EBITDA, our habit has always been to err on the side of caution. Inside the company, we build our plans around the worst-case scenario, and what you're looking at reflects exactly those figures, while ideally we're keeping our fingers crossed for the best outcome. Should things get better, we'll go ahead and lift that guidance yet again, provided that chance comes along once the following quarter wraps up. Broadly speaking, though, the culture here at Cloud Cultures is to stay cautious — prepare for the worst and hope for the best.

Analyst

analyst
#35

Could you also give us a brief update on whether there's any seasonality we should keep an eye on for the transportation side during 3Q and heading into 4Q? And how did that business perform relative to what you were expecting internally this quarter? I believe you reduced transport mix as a share of total by 1 percentage point, and my guess is that reflects some outperformance in COVID revenues within mobile health, but did it meet what you were hoping to see there in 2Q?

Stan Vashovsky

executive
#36

Yes. Look, we find a great deal of worth in our transportation business, though that portion of our operations is shrinking somewhat. It might keep doing so as time goes on, we'll see; we appreciate that business since it's recurring, it's stable, it's nearly annuity like. It additionally provides us with access to many patients who might eventually need our mobile health services. So obviously we direct our efforts; we concentrate our strength on our higher revenue, higher gross margin, more profitable business, which is mobile health. Yet we remain strategically dedicated to our transportation business. We continue to observe solid, consistent expansion in that business. And what we're quite occupied with doing is we move enormous numbers of thousands of people each and every day; so what we're very busy doing is asking, Hey we have someone in our vehicle, we're bringing them home. We understand the reason they're being released. Well, what additional services can we provide to that patient now? And eventually take a patient who was solely transport revenue and have that patient add in the future to our mobile health revenue. And that's the sort of thing we're constantly considering and innovating on.

Ryan MacDonald

analyst
#37

Nice work on a strong quarter. Stan, I've got the first question for you; it's wonderful to watch the — the traction you're beginning to gain in the payer end market. That said, reaching member populations now demands that DocGo develop a fresh capability, since you have to market two members inside that population, so I'd love to hear how things are progressing so far in the beta test and perhaps what you anticipate as this scales, in terms of the penetration you believe you can achieve among those member populations. And finally, do you expect any revenue, or a meaningful revenue contribution, from these contracts during the back half of this year?

Stan Vashovsky

executive
#38

The truth is we're not assuming any revenue, or any meaningful revenue, from those payers through the remainder of 2022; we anticipate a modest contribution to ‘23. We see enormous potential there, in our direct-to-consumer future offering, where results are coming in extremely strong, but Ryan, as you might expect, we never do anything the traditional way, and we recognize that with a conventional direct to consumer offering, customer acquisition costs are able to climb quite high. That's something we know. So we're working and thinking in a highly creative manner. How can we connect with millions of patients who could benefit from our service, yet do so in a non-traditional manner that gives us access to large numbers of people at extremely low cost; and until we crack that, we'll continue testing a variety of different approaches. At present, the pilots are performing very well in New York and New Jersey. I'd say we're tracking slightly ahead of plan versus what we had expected, though we still have a long way to go before truly arriving at a direct-to-consumer plan we feel super, super confident about; and once that occurs, and we hope it occurs at some point in 2023, it will unlock an enormous TAM, one we aren't even tapping into at this moment.

Ryan MacDonald

analyst
#39

Then, perhaps, only to continue on that, I found it quite interesting to learn about the refreshed technical connections involving Athena health and also the fact that you have been welcomed into the epic app orchard. I would be curious to know, during your discussions with health systems, to what extent has this previously perhaps acted as a limiting element that could have stopped possibilities from coming to fruition, and what is your view on the effect upon the pipeline now that you possess these seamless connections with two leading EHRs?

Stan Vashovsky

executive
#40

Brian, I am going to have Anthony, the President we have, respond to that.

Anthony Capone

executive
#41

The biggest hurdle I see for many companies working with health systems is this: they try to convince the system to take on their software. Basically, it's an entirely new app, and a hospital system might have thousands — tens of thousands — of staff members. So they're trying to get all those tens of thousands of people to adopt their new web portal, their new application. As soon as you're integrated into their EHR, that whole problem goes away. What we have is single sign-on, so with one click from within the patient's chart, you're in. The data integrates seamlessly — everything about the patient's demographics, their payer details, and charting information, including H&P, flows directly into your application. Once you reach that point, there's essentially no barrier left. That's the capability the Epic App Orchard gives us. Now, plenty of companies enter the Epic App Orchard and it amounts to nothing more than a hyperlink — you're sitting inside Epic, and from there it opens your application. We chose a different path. Our approach keeps the whole journey, from beginning to completion, within Epic. Then everything flows back into Epic, allowing the health system to handle all its reporting, KPIs, and metrics right inside their own application, with no need to reach out to us for any of it. That truly removes the obstacle. Now, regarding the second half of your question about what this unlocks: Epic holds the largest user base and is expanding more quickly than any other EHR among hospitals and health systems. That's really a positive sign for our team, since the Epic app portrait can now be accessed by everybody within that area.

Stan Vashovsky

executive
#42

And Ryan, I want to build on that point. When we walk into a hospital system — a major hospital system — and we share with them what we'd like to accomplish together, and we explain that they can get even more out of the investment they've already made in Epic by using our technology, that makes the sale far more appealing than anything a competitor could possibly put on the table. Think about the barriers to entry: finishing that integration required years. It required millions of dollars, and above all, it required major hospital systems to vouch for us with Epic so that we could obtain the support necessary to see this effort through. This whole thing was extremely complex, costly, and time-intensive. The sole reason we managed to pull it off is that the big hospital systems we have relationships with went to bat for us. None of our competitors enjoy that benefit today, and that's something we're really enthusiastic about, and something we believe will keep fueling our growth going forward, since we're telling hospitals: simply get more out of what you've already invested — hundreds of millions of dollars — by taking advantage of our services.

Craig Jones

analyst
#43

So Stan, you brought up that your biggest partner for mass COVID testing was transitioning into merely a mobile health contract. Out of that 28 million you generated in 2Q from mass COVID, what portion are you factoring in for 3Q and 4Q — whether mobile, COVID, or whatever label you prefer?

Stan Vashovsky

executive
#44

Extremely minimal — we essentially have only the basics through August. A couple of days into September, and after that the whole program disappears. So you're looking at — we don't provide segment reporting on specific projects. But what I'd say is there will be very minimal mass COVID testing revenue moving forward. That's exactly why, as Andre pointed out, we have no real intention of reporting it as its own line item in future periods; it falls far below the threshold of materiality; and it simply requires far too much effort and far too much work to keep up, something that brings in a few million here and there. It is not what separating out for us.

Craig Jones

analyst
#45

Yeah. My apologies. Perhaps that wasn't the question. Well, okay, what I meant was this — since your customer has moved over to mobile health, how significant a contributor to quarterly revenue are they going to be, from that mobile health angle?

Stan Vashovsky

executive
#46

Looking at it that way, I'd tell you that you can essentially assume a pretty comparable figure, or possibly even somewhat above, compared with the revenue they were bringing in back when they were handling COVID testing.

Craig Jones

analyst
#47

Alright. So the expectation is that most of that 28 million carries on, just under a different agreement, under mobile, right?

Stan Vashovsky

executive
#48

Yes — a different agreement covering the traditional mobile health services. That's right.

Craig Jones

analyst
#49

All right, understood. Then regarding carnival, I believe mobile health expanded roughly 13%, 14% quarter over quarter, and setting aside COVID, that accounted for most of the carnival ramp-up. Then, considering the ARR, how near are we to reaching it — I suppose where does it stand today on a monthly or annual recurring basis — and what's the ceiling for it?

Stan Vashovsky

executive
#50

Carnival certainly played a part. Other cruise lines contribute as well. Additional hospitals and municipalities are contributors too; yet another angle you might take is that the entirety, or a very large share, of the COVID testing revenue is set to turn into mobile health revenue. So any growth you observe presently in mobile health that leaves out mass COVID testing down the road — you can essentially project that revenue will fold into mobile health. And that proportion of mobile health growth is going to rise substantially in Q3 and Q4.

Craig Jones

analyst
#51

Understood. All right, then when we turn to the guidance, it appears to suggest a sequential decline in the third quarter and fourth quarter compared with the first half for mobile health — or, I suppose, yes, likely for mobile health. So assuming that customer is mostly moving away from mass COVID toward mobile, what is causing that headline figure, and why would it point to a sequential decline?

Stan Vashovsky

executive
#52

As we touched on previously, our stance has consistently been quite cautious. A lot can take place throughout the transition. We remain quite optimistic about how the back half of the year shapes up, yet we are understandably being cautious, and once the third quarter wraps up, should our caution prove excessive, we will simply lift guidance again.

Richard Close

analyst
#53

Stan, I wanted to ask you to expand a bit on the RFP. You said something about activity picking up. Could you go into more detail? Is any of that included in your guidance, or is it all potential upside? And for those kinds of contracts, what does a typical one look like?

Stan Vashovsky

executive
#54

As far as including anything in our guidance, no — our guidance is built on contracts and agreements we have a lot of confidence in. When it comes to the RFP side, we can tap into many municipal and government systems, which lets us observe what the needs are across different municipalities nationwide; we likely bring more experience with large medical programs than anyone else in the market right now. And we have fantastic clients who are ready to serve as references for those kinds of services. So we've observed that 3x growth in our responses to those RFPs. We win a portion of them, and they may be small contracts, but at this point we're really zeroing in on some of the big ones — contracts from the CDC department of homeless services, plus municipalities, border patrol. There are medical services from very large agencies, dozens of them, that appear every couple of months, and more than ever we're responding to those, and gradually we're beginning to win a few.

Stan Vashovsky

executive
#55

All right, that wraps up this morning's call. We kicked off 2022 with obvious and substantial momentum throughout our operations. And I feel optimistic that we've laid the groundwork for a highly successful year. I'm eager for our next quarterly update, which comes in November. Thanks to all of you for being with us.

Operator

operator
#56

That brings us to the end of today's call. We appreciate your participation. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DocGo Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DocGo Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DocGo Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.